Demanda colectiva por productos para bebés de Johnson & Johnson

The Headline Number

Johnson & Johnson said Monday it will pay an estimated $5.5 billion to resolve roughly 76,000 lawsuits claiming its iconic baby powder and other talc products caused ovarian cancer — a deal plaintiffs' firms are calling long-delayed justice after ten years of trench warfare in courtrooms from New Jersey to Missouri (Law360, Reuters).reuters+1

But "$5.5 billion" is the floor, not the ceiling. The agreement covers claims consolidated in the federal MDL in New Jersey along with related state-court cases — effectively nearly all of the talc litigation J&J still faces on the ovarian cancer side.reuters

How the Money Actually Moves

This is not a fixed settlement fund divided among claimants — it's a tiered, per-claim grid. Compensation will be assigned to each qualifying ovarian cancer claim based on objective criteria, meaning the aggregate payout floats with participation rather than being capped at a set number (GlobeNewswire/Levin Papantonio, MDLUpdate).globenewswire+1

Christopher Seeger of Seeger Weiss, who represents roughly 2,500 talc clients and helped negotiate the deal, told Reuters that J&J could ultimately pay $7 billion or more once all qualifying claims are counted — and that the structure "does not cap J&J's total payout". On timing, J&J says it expects to pay no more than $3 billion in 2027, with additional payments following in 2028 (Reuters; NJBIZ). Seeger says the accelerated schedule would resolve claims within roughly 18 months — a sharp contrast to the more-than-a-decade timeline that would have applied under J&J's earlier, rejected bankruptcy plans.njbiz+1

The Catch: This Isn't Final Yet

The deal only takes effect if at least 95% of the remaining ovarian cancer claimants formally sign on (MDLUpdate; NJBIZ). The Plaintiffs' Executive Committee has unanimously endorsed it, but enrollment deadlines and other participation conditions still stand between announcement and closure.globenewswire+2

Two more caveats worth flagging for anyone tracking the litigation closely:

• Existing claims only. Unlike J&J's three failed "Texas Two-Step" bankruptcy plans, this settlement resolves only current and pending claims — it does not attempt to extinguish future lawsuits, which is part of why plaintiffs' counsel are framing it favorably compared to prior offers (Reuters; NJBIZ).njbiz+1

• Mesothelioma is a separate track. This deal is specific to ovarian cancer claims. J&J says it had already resolved about 95% of filed mesothelioma lawsuits tied to alleged asbestos contamination in its talc, and those remain on their own settlement path.mdlupdate

Why Now? A Loss That Looked Like a Win

The timing is not incidental. The announcement came days after a July 22 order requiring plaintiffs to show cause why remaining claims shouldn't be dismissed for failure to prove specific causation — after two of plaintiffs' causation experts were withdrawn from the litigation. Reuters likewise reports J&J came to the table on the back of a string of favorable rulings: individual trial wins, successful motions disqualifying plaintiffs' counsel in parts of the litigation, and adverse rulings against plaintiffs' expert witnesses.reuters+1

In other words: this settlement arrived not from a plaintiffs'-side courtroom triumph, but from a moment of real litigation risk for the claimants — which makes the deal's size, and counsel's willingness to call it a win, notable.

The Talking Points on Both Sides

J&J's Erik Haas, the company's worldwide vice president of litigation, stuck to the company's decade-long script — calling the claims "meritless" while framing the payout as a business decision:

"While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives."reuters

Plaintiffs' firms, unsurprisingly, told a different story. Seeger called it "a fair settlement," predicting clients "are going to be happy with it". Christopher Tisi, one of the plaintiffs' attorneys, put it in starker terms:reuters

"We have been battling Johnson & Johnson in and out of court for years. We have watched countless clients suffer grievously from J&J's deception. I am proud to say that this settlement will provide resolution to the lawsuits. Nothing can restore the health or the lives of those who have died from asbestos cancers."globenewswire

The Backstory: Three Bankruptcies, Zero Success

This is J&J's fourth attempt at a comprehensive resolution — and its first that doesn't run through bankruptcy court. The company tried the so-called Texas Two-Step maneuver three times, shuffling talc liabilities into a shell subsidiary and then putting that subsidiary into Chapter 11: first in New Jersey (dismissed twice) and later in Texas (Reuters; Drugwatch). Each attempt collapsed — the Third Circuit tossed the first, and a Texas bankruptcy judge rejected the most recent $9 billion version in April 2025. Litigation resumed in earnest in March 2025 after being effectively frozen for more than three years while those bankruptcy fights played out.reuters+1

J&J pulled its talc-based baby powder from U.S. shelves in 2020, replacing it with a cornstarch formulation, while continuing to insist — as it does today — that the product never contained asbestos and never caused cancer.reuters

What to Watch Next

• Whether the 95% participation threshold is reached, and on what timeline for enrollment.

• The mechanics of the per-claim grid — plaintiffs' firms have not published individual payout ranges, and any number circulating for what a given claimant will receive should be treated as unverified until the claims administrator publishes the criteria.

• Whether the accelerated 18-month payment structure holds, given J&J's history of settlement proposals that stalled or were rejected outright.

• ​

This summary is compiled from Law360, Reuters, MDLUpdate, NJBIZ, and the plaintiffs' firms' own press materials, with direct quotes attributed to their original sources above. Given the press interest already surrounding this litigation, any figures pulled for public use should be traced back to these primary reports rather than secondary aggregation.

​

Submissions have ended

​

​